000271085 001__ 271085
000271085 005__ 20240814121440.0
000271085 037__ $$aDZNE-2024-00957
000271085 1001_ $$0P:(DE-2719)9002232$$aDehestani, Mohammad$$b0$$udzne
000271085 245__ $$aDataset: Transcriptomic changes in oligodendrocytes and precursor cells predicts clinical outcomes of Parkinson's disease
000271085 260__ $$bGene Expression Omnibus$$c2024
000271085 3367_ $$2BibTeX$$aMISC
000271085 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1723625220_28440
000271085 3367_ $$026$$2EndNote$$aChart or Table
000271085 3367_ $$2DataCite$$aDataset
000271085 3367_ $$2ORCID$$aDATA_SET
000271085 3367_ $$2DINI$$aResearchData
000271085 520__ $$aSeveral prior studies have proposed the involvement of various brain regions and cell types in Parkinson's disease (PD) pathology. Here, we performed snRNA-seq on the prefrontal cortex and anterior cingulate regions from post-mortem control and PD brain tissue. We found a significant association of oligodendrocytes (ODCs) and oligodendrocyte precursor cells (OPCs) with PD-linked risk loci and report several dysregulated genes and pathways, including regulation of tau-protein kinase activity, regulation of inclusion body assembly and protein processing involved in protein targeting to mitochondria. In an independent PD cohort with clinical measures (681 cases and 549 controls), polygenic risk scores derived from the dysregulated genes significantly predicted Montreal Cognitive Assessment (MoCA)-, and Beck Depression Inventory-II (BDI-II)-scores but not motor impairment (UPDRS-III). We extended our analysis of clinical outcome prediction by incorporating three separate datasets that were previously published by different laboratories. In the first dataset from the anterior cingulate cortex, we identified a correlation between ODCs and BDI-II. In the second dataset obtained from the substantia nigra (SN), OPCs displayed notable predictive ability for UPDRS-III. In the third dataset from the SN region, a distinct subtype of OPCs, labeled OPC_ADM, exhibited predictive ability for UPDRS-III. Intriguingly, the OPC_ADM cluster also demonstrated a significant increase in PD samples. These results suggest that by expanding our focus to glial cells, we can uncover region-specific molecular pathways associated with PD symptoms.
000271085 536__ $$0G:(DE-HGF)POF4-354$$a354 - Disease Prevention and Healthy Aging (POF4-354)$$cPOF4-354$$fPOF IV$$x0
000271085 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000271085 7001_ $$0P:(DE-HGF)0$$aKozareva, V.$$b1
000271085 7001_ $$0P:(DE-2719)2810837$$aBlauwendraat, Cornelis$$b2
000271085 7001_ $$0P:(DE-HGF)0$$aFränkel, E.$$b3
000271085 7001_ $$0P:(DE-2719)2320009$$aGasser, Thomas$$b4$$udzne
000271085 7001_ $$0P:(DE-2719)2812055$$aBansal, Vikas$$b5$$udzne
000271085 8564_ $$uhttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272760
000271085 909CO $$ooai:pub.dzne.de:271085$$pVDB
000271085 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002232$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000271085 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2320009$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000271085 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812055$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000271085 9131_ $$0G:(DE-HGF)POF4-354$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Prevention and Healthy Aging$$x0
000271085 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000271085 9141_ $$y2024
000271085 9201_ $$0I:(DE-2719)1210013$$kAG Bansal$$lBiomedical Data Science$$x0
000271085 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x1
000271085 980__ $$adataset
000271085 980__ $$aVDB
000271085 980__ $$aI:(DE-2719)1210013
000271085 980__ $$aI:(DE-2719)1210000
000271085 980__ $$aUNRESTRICTED